KLRK1 and neoplasm: Although only a limited number of clinical trials have evaluated CAR-NK products based on NK92, PB-NK, and UCB-NK cells, there is growing interest in targeting common tumor antigens like Roundabout homolog 1 (ROBO1), NK cell-activating receptor (NKG2D), MSLN, HER2, and MUC1.